ArticleAmerican journal of reproductive immunology (New York, N.Y. : 1989)2026
Interleukin-6 Downregulates T Helper 17 Cytokines via Indoleamine 2,3-Dioxygenase 1 at the Maternal-Fetal Interface.
Article in American journal of reproductive immunology (New York, N.Y. : 1989), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
Abstract
backgroundThe cytokines interleukin (IL)-6 and transforming growth factor-beta (TGF-β) are established inducers of pathogenic T helper 17 (Th17) cells from naïve T cells. In the maternal-fetal compartment, IL-6 signaling elevates levels of indoleamine 2,3-dioxygenase 1 (IDO1). This study investigated whether IL-6 regulates Th17 cytokine production through IDO1.
methodsHuman decidua and chorionic villi (HDCV) were collected from normal early pregnant women undergoing elective termination. For HDCV culture, explants were treated with increasing doses of IL-6 (0-50 ng/mL) or co-treated with IL-6 and the IDO1 inhibitor 1-methyltryptophan (1-MT) for 24 h. HDCV were also treated with IL-6 (5 ng/mL) alone or in combination with TGF-β (0.01-0.1 ng/mL) for 24 h. Recurrent pregnancy loss (RPL) mice were intraperitoneally injected with IL-6 (2, 10, or 50 ng/mL), alone or combined with 1-MT and/or Cosentyx, from gestational day (GD) 0.5 to 8. Protein expression levels of IL-6, IDO1, IL-17, and IL-22 were assessed by Western blotting and immunohistochemistry. Embryo absorption rate (EAR) was calculated on GD 12.5. Cytokine concentrations in supernatants or serum were measured using enzyme-linked immunosorbent assay.
resultsIn HDCV tissues, IL-6 positively correlated with IDO1 and negatively correlated with IL-17/IL-22. Exogenous IL-6 dose-dependently upregulated IDO1 and suppressed IL-17/IL-22 in cultured explants, effects reversed by 1-MT. Physiological TGF-β1 (0.01-0.1 ng/mL) enhanced IL-6-induced IDO1 upregulation and Th17 cytokine suppression. In RPL mice, IL-6 reduced EAR and placental IL-17/IL-22 expression while increasing IDO1; these effects were blocked by 1-MT and restored by Cosentyx.
conclusionsDuring normal pregnancy, IL-6 alone or the combination of IL-6 and TGF-β at the maternal-fetal interface may inhibit Th17 cytokine production by upregulating IDO1 expression, thereby maintaining pregnancy stability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.